HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human
HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human

Immobilized HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC50 of 5.8 ng/ml determined by ELISA.

HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human

The purity of HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human

HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human

HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.
Z06648
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide]
Accession # P17693-1(HLA-G)&P61769(B2M)&RIIPRHLQL		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 50.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human
    • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human

    Immobilized HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC50 of 5.8 ng/ml determined by ELISA.

  • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human
    • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human

    The purity of HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human
    • HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human

    HLA-G&B2M&Peptide (RIIPRHLQL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.
Synonyms HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.